Integra LifeSciences extends $150M A/R facility

Integra LifeSciences Holdings Corporation amended its existing $150 million accounts receivable securitization facility, originally entered into in 2018, by executing amendments to its Receivables Financing Agreement and Purchase and Sale Agreement.

Rhea-AI Filing Summary

Integra LifeSciences Holdings Corporation amended its existing $150 million accounts receivable securitization facility, originally entered into in 2018, by executing amendments to its Receivables Financing Agreement and Purchase and Sale Agreement.

The amendments extend the facility’s scheduled termination date to April 10, 2029 and adjust certain customary representations, covenants and concentration limits related to the receivables backing the facility. These changes are intended to keep the funding structure in place to support ongoing liquidity and working capital needs.

Insights

Credit & capital structure analyst

Integra extends a key $150M receivables facility to 2029, preserving liquidity.

Integra LifeSciences maintains access to a $150 million accounts receivable securitization facility by extending its scheduled termination date to April 10, 2029. This structure allows the company to borrow against eligible customer receivables instead of relying solely on its senior credit facility.

The amendments also revise customary representations, covenants and receivable concentration limits under the Receivables Financing Agreement and Purchase and Sale Agreement. While details are not listed here, such changes typically refine eligibility and risk parameters rather than altering overall borrowing capacity.

Overall, this is a neutral but supportive capital-structure move. It helps preserve a diversified funding mix and ongoing liquidity for business needs, without indicating any new financial distress or transformational change on its own.

8-K Event Classification

Item 1.01 — Entry into a Material Definitive Agreement

1 item

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Key Figures

A/R facility size: $150 million Facility termination date: April 10, 2029 Original A/R facility date: December 18, 2018 +1 more

4 metrics

A/R facility size $150 million Accounts receivable securitization facility originally entered into December 18, 2018

Facility termination date April 10, 2029 Scheduled termination date after April 2026 amendments

Original A/R facility date December 18, 2018 Date certain subsidiaries entered the receivables facility

Amendment execution date April 10, 2026 Date of RFA Amendment and PSA Amendment

Key Terms

accounts receivable securitization facility, Receivables Financing Agreement, Purchase and Sale Agreement, scheduled termination date, +1 more

5 terms

accounts receivable securitization facility financial

"entered into a $150 million accounts receivable securitization facility (the “A/R Facility”)"

A accounts receivable securitization facility is a financing arrangement where a company converts its unpaid customer invoices into immediate cash by selling them or using them as collateral for a line of credit. Think of it like using a stack of IOUs as a short-term loan to smooth cash flow; it matters to investors because it changes a company’s liquidity, borrowing profile and risk exposure without necessarily showing up as traditional debt, affecting valuation and credit health.

Receivables Financing Agreement financial

"included (i) a Receivables Financing Agreement (the “RFA”)"

Purchase and Sale Agreement financial

"and (ii) a Purchase and Sale Agreement (the “PSA”)"

A purchase and sale agreement is a legally binding contract that spells out exactly what is being bought or sold, the price, who must do what, the timeline, and any conditions that must be met before the deal closes — like a detailed recipe and checklist for a transaction. Investors care because this document determines when ownership or assets change hands, what risks or obligations remain, and which conditions (financing, approvals, inspections) could delay, alter, or void the deal and therefore affect a company’s value and stock price.

scheduled termination date financial

"extends the scheduled termination date of the A/R Facility to April 10, 2029"

concentration limits financial

"and the customary concentration limits applicable to the receivables in the A/R Facility"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Integra LifeSciences (IART) change in its A/R facility?

Integra LifeSciences amended its accounts receivable securitization facility, updating the Receivables Financing Agreement and Purchase and Sale Agreement. The changes extend the facility’s scheduled termination date and revise certain customary representations, covenants, and receivable concentration limits that govern how the facility operates and manages risk.

How large is Integra LifeSciences’ accounts receivable securitization facility?

The accounts receivable securitization facility is sized at $150 million. This structure lets Integra LifeSciences borrow against qualifying customer receivables, providing an additional source of liquidity alongside its senior credit facility to support ongoing working capital and general business funding needs.

Until when has Integra LifeSciences extended its A/R facility?

Integra LifeSciences extended the scheduled termination date of its accounts receivable securitization facility to April 10, 2029. This multi‑year extension helps ensure continued access to this funding source, supporting liquidity planning and reducing near‑term refinancing pressure on this portion of its capital structure.

Which agreements did Integra LifeSciences amend in April 2026?

In April 2026, Integra LifeSciences executed Amendment No. 8 to its Receivables Financing Agreement and Amendment No. 1 to its Purchase and Sale Agreement. These documents govern how receivables are sold and financed within the $150 million securitization facility structure with participating lenders.

Why does Integra LifeSciences use an accounts receivable securitization facility?

Integra LifeSciences uses the $150 million accounts receivable securitization facility to reduce outstanding revolving borrowings under its senior credit facility and provide additional liquidity. By financing eligible receivables, the company can support ongoing business needs while diversifying its short‑term funding sources.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 04:24 PM Learn about SEC filing dates

0000917520false00009175202026-04-102026-04-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2026

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware			0-26224			51-0317849
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)

1100 Campus Road

Princeton, NJ 08540

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities Registered Pursuant to Section12(b) of the Act:

Title of Each Class			Trading Symbol			Name of Exchange on Which Registered
Common Stock, Par Value $.01 Per Share			IART			Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

As previously disclosed, on December 18, 2018, certain subsidiaries of Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), entered into a $150 million accounts receivable securitization facility (the “A/R Facility”) to reduce outstanding revolving borrowings under the Company’s senior credit facility and to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries.

The documentation for the A/R Facility included (i) a Receivables Financing Agreement (the “RFA”) entered into by and among Integra Receivables LLC, a Delaware limited liability company and a bankruptcy-remote special purpose entity that is an indirect, wholly-owned subsidiary of the Company (the “Borrower”), Integra LifeSciences Sales LLC (“ILS Sales”), as Servicer (the “Servicer”), PNC Bank, National Association (“PNC”), as Administrative Agent, PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time and (ii) a Purchase and Sale Agreement (the “PSA”) by and among ILS Sales, Integra LifeSciences Corporation, and certain other subsidiaries of the Company party thereto from time to time, as Originators, the Servicer and the Borrower.

On April 10, 2026, (i) the Borrower and ILS Sales entered into Amendment No. 8 to Receivables Financing Agreement (the “RFA Amendment”), by and among the Borrower, ILS Sales, as Servicer, PNC, as Administrative Agent and Committed Lender, The Bank of Nova Scotia, as Committed Lender and Group Agent, PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time and (ii) the Borrower and ILS Sales entered into Amendment No. 1 to Purchase and Sale Agreement(the “PSA Amendment,” and together with the RFA Amendment, the “April 2026 Amendments”), by and between the Borrower, as Buyer and ILS Sales, as Servicer, and acknowledged and agreed by PNC, as Administrative Agent.

The RFA Amendment, among other things, extends the scheduled termination date of the A/R Facility to April 10, 2029, and implements amendments to certain customary representations and covenants under the RFA and the customary concentration limits applicable to the receivables in the A/R Facility. The PSA Amendment implements amendments to certain customary representations and covenants under the PSA.

The foregoing descriptions of the RFA Amendment and the PSA Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the RFA Amendment and the PSA Amendment, which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: April 15, 2026			By:			/s/ Lea Knight
						Lea Knight
			Title:			Executive Vice President and Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 14.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 24.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 14.6 KB